Search company, investor...

Predict your next investment

Corporate Venture
helsinninvestmentfund.com

Investments

32

Portfolio Exits

4

Funds

2

Partners & Customers

5

About 3B Future Health Fund

3B Future Health Fund is focused on early-stage investment opportunities in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn's core values of quality, integrity and respect, 3B Future Health Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.

Headquarters Location

Le Montaigne 7-9 Avenue de Grande Bretagne

MC-98000,

Monaco

+377 97 98 30 80

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest 3B Future Health Fund News

GenEp Raises $1.45 Million Seed Financing

May 31, 2023

Financing will support development of first-in-class CNS-selective sodium channel modulators CHARLOTTESVILLE, VA / ACCESSWIRE / October 26, 2021 / GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira Biosciences Fund and 3B Future Health Fund, with additional participation by the Virginia Innovation Partnership Corporation, Kids Connect Charitable Fund, PDI Ventures and the company's management team. GenEp is developing first-in-class, highly selective compounds that modulate sodium channels. Nav1.6 & Nav1.2 gain of function mutations drive uncontrolled seizures and result in treatment resistance in certain rare genetic epilepsies and other treatment resistant epilepsies. "We are grateful to our investors for their confidence in our team and our science," said Andrew J. Krouse, President and Chief Executive Officer of GenEp. "Their financial support and deep industry experience will enable our company to make a difference in the lives of children and families living with epilepsy." The company's proprietary mouse audiogenic reflex seizure model (MARSTM) allows it to rapidly screen many compounds in vivo in a clinically relevant model of human SCN8A epileptic encephalopathy, a rare pediatric disease caused by gain of function mutation in the Nav1.6 channel. Based on the University of Virginia's Dr. Manoj Patel's therapeutic insight that targeting the CNS isoforms of the Nav channel (Nav1.6, Nav1.2, and Nav1.1) to control seizures would be superior to targeting only Nav1.6, GenEp is optimizing its patented first series of CNS- specific sodium channel inhibitors to decrease over-active neuronal signaling while limiting off-target safety effects common to other isoforms and ion channels. "We are excited to join in accelerating GenEp's important pediatric genetic epilepsy programs," stated Gerry Brunk, Managing Director of Lumira Ventures, manager of the Angelini Lumira Biosciences Fund. "GenEp's experienced management team (whose previous company Cavion was acquired by Jazz Pharmaceuticals in 2019), patented compounds, and innovative drug screening model offer a compelling opportunity to develop effective therapies for these patients' unmet medical needs." In connection with the financing, Gerry Brunk and Marianne Bjordal of 3B Future Health Fund will join CEO Andrew Krouse on the GenEp Board of Directors. About GenEp, Inc. GenEp, Inc. is a privately held pre-clinical stage biotechnology company based on intellectual property assets licensed from the University of Virginia. GenEp aims to create therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. About the UVA Licensing & Ventures Group The Licensing & Ventures Group (LVG) is the intellectual property management and innovation commercialization organization for the University of Virginia (UVA) research enterprise. Founded in 1977, its mission is to maximize the intellectual, societal, and economic impact of UVA discoveries via commercialization to enrich and improve lives for the University, the Commonwealth of Virginia, and the world. The LVG Seed Fund is a $10MM evergreen fund that is uniquely positioned to launch and support new ventures emerging from the UVA research portfolio. The Fund is governed by an oversight committee comprised of leaders in early-stage investing and startup development who are all UVA alumni. To learn more visit lvg.virginia.edu . About Angelini Lumira Biosciences Fund Angelini Lumira Biosciences Fund is a corporate venture capital fund established by Angelini Pharma, an international pharmaceutical company, part of the Italian privately-owned Angelini Group. Angelini Pharma is committed to helping patients in the therapeutics areas of central nervous system and mental health, rare diseases, and consumer healthcare. Angelini Pharma operates directly in 25 countries employing almost 3,000 people and commercializes its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups. About 3B Future Health Fund S.A. SICAR, formerly known as Helsinn Investment Fund S.A., SICAR 3B Future Health Fund is focused on investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn's core values of quality, integrity, and respect, 3B Future Health Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients. Drawing on Helsinn's over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions. For more information, please visit 3bfuturehealth.com . Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. GenEp, Inc. disclaims any intent or obligation to update forward-looking statements, except as required by law. Contacts

3B Future Health Fund Investments

32 Investments

3B Future Health Fund has made 32 investments. Their latest investment was in NeoPhore as part of their Series B - III on February 01, 2024.

CBI Logo

3B Future Health Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/1/2024

Series B - III

NeoPhore

$12.2M

No

2

11/16/2023

Series C

On Target Laboratories

$30M

No

1

8/22/2023

Series D

FORE Biotherapeutics

$75M

No

2

5/31/2023

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

5/12/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/1/2024

11/16/2023

8/22/2023

5/31/2023

5/12/2023

Round

Series B - III

Series C

Series D

Seed VC - II

Series D

Company

NeoPhore

On Target Laboratories

FORE Biotherapeutics

Subscribe to see more

Subscribe to see more

Amount

$12.2M

$30M

$75M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

2

10

10

3B Future Health Fund Portfolio Exits

4 Portfolio Exits

3B Future Health Fund has 4 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/23/2021

Acquired

$99M

12

5/17/2021

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

3/18/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/23/2021

5/17/2021

3/18/2021

7/15/2019

Exit

Acquired

Acq - P2P

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

12

10

10

10

3B Future Health Fund Fund History

2 Fund Histories

3B Future Health Fund has 2 funds, including Helsinn Investment Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/12/2016

Helsinn Investment Fund

$50M

1

3B Future Health Fund II

10

Closing Date

10/12/2016

Fund

Helsinn Investment Fund

3B Future Health Fund II

Fund Type

Status

Amount

$50M

Sources

1

10

3B Future Health Fund Partners & Customers

5 Partners and customers

3B Future Health Fund has 5 strategic partners and customers. 3B Future Health Fund recently partnered with MEI Pharma on February 2, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

2/14/2019

Licensor

United States

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances

In August 2016 , Helsinn Investment Fund and MEI Pharma , Inc. entered into an exclusive license , development and commercialization agreement for pracinostat in AML and other potential indications .

2

12/20/2018

Partner

Italy

Subscribe to see more

Subscribe to see more

10

7/20/2018

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

1/30/2018

Partner

Monaco

Subscribe to see more

Subscribe to see more

10

3/21/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

2/14/2019

12/20/2018

7/20/2018

1/30/2018

3/21/2017

Type

Licensor

Partner

Partner

Partner

Partner

Business Partner

Country

United States

Italy

South Korea

Monaco

United States

News Snippet

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances

In August 2016 , Helsinn Investment Fund and MEI Pharma , Inc. entered into an exclusive license , development and commercialization agreement for pracinostat in AML and other potential indications .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.